Clinical Trial

Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication

Study acronym: Nor-vaC
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2024 (before its estimated February 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive and/or immunomodulating medication for immune-mediated inflammatory diseases in rheumatology and gastroenterology and after a liver transplantation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-03-12; most recent amendment 2024-02-22.
Status change: Recruiting → Active, Not Recruiting 2021-10-07
Trial Details
NCT Number NCT04798625
Lead Sponsor Diakonhjemmet Hospital
Collaborators: University Hospital, Akershus
Conditions Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthritis, Crohn Disease, Ulcerative Colitis, Autoimmune Hepatitis, Liver Transplant; Complications
Enrollment 2,300 participants
Start Date 2021-02-15
Primary Completion 2026-02-15 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2024-02-23